TREATMENT OF THE T3—4N0M0 BREAST CANCER
https://doi.org/10.17650/1994-4098-2008-0-1-20-24
Abstract
The aim of the study was to determine the most effective regimens of the neo- and adjuvant therapy of the primary breast cancer of the T3—4N0M0 stages. The data of the clinical observations of the 145 patients with the locally advanced T3—4N0M0 breast cancer, who underwent treatment in the N.N.Blokhin CRC over the period of 1998—2003, were used in the study. The mean age of the patients was 55,3±12,9 years (from 19 to 83 years, median-55 years). The duration of the observation of the patients was 46,5±28,51 months (from 3,6 to 109,4 months, median-44,5 months). For patients with the breast cancer of the T3—4N0M0 stages combined treatment modality was implemented with the use of neo- and adjuvant therapy in all the cases.
About the Authors
K. V. Maximov
N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
I. V. Visotzkaya
N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
V. D. Yermilova
N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
V. P. Letyagin
N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
Ye. M. Pogodina
N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
G. Yu. Chemeris
N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
A. D. Zikiryakhodzhayev
N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
Ye. A. Kim
N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
G. V. Martinova
N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ. М.; 2005.
2. Давыдов М.И., Летягин В.П. Стандарты лечения больных первичным раком молочной железы. М.; 2003.
3. Возный Э.К., Добровольская Н.Ю., Гуров С.Н. Некоторые аспекты неоадъювантной терапии местнораспространенного рака молочной железы. Юбилейный сборник «Этюды химиотерапии». М.; 2000. с. 90—8.
4. Летягин В.П. Первичные опухоли молочной железы. Практическое руководство по лечению. М., Миклош; 2004.
5. Летягин В.П., Погодина Е.М., Высоцкая И.В. и др. Лечение больных раком молочной железы стадии T2N1M0 — T3N0M0. Высокие технологии в онкологии. Материалы V Всероссийского съезда онкологов. Казань, 4—7 октября 2000 г. Т. 3. с. 55—6 (б).
6. Портной С.М., Лактионов К.П., Барканов А.И. Опыт лечения больных прогностически отягощенным местнораспространенным раком молочной железы. IV Ежегодная российская онкологическая конференция. Москва, 21—23 ноября 2000 г. с. 57—9.
7. Портной С.М, Лактионов К.П., Барканов А.И. Предварительные результаты органосохраняющих операций при раке молочной железы T2—3N0—2M0 после эффективной неоадьювантной терапии. Herald of the International Association of Plastic Surgeon and Oncologists, 2003;4:35.
8. Coskun U., Gunel N., Onuk E. et al. Effect of different neoadjuvant chemotherapy regiments on locally advanced breast cancer. Neoplasma 2003;50(3):210—6.
9. Gajdos C., Tartter P.I., Bleiweiss I.J. et al. Stage 0 to stage III breast cancer in young women. J Am Coll Surg 2000;190(5):523—9.
10. Kaufmann M., Hortobagyi G.N., Goldhirsch A. et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006;24:1940—9.
11. Kaufmann M., von Minckwitz G., Rody A. Preoperative (neoadjuvant) sys- temic treatment of breast cancer. Breast 2005;14:576—81.
12. Mauri D., Pavlidis N., Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment for breast cancer: a meta- analysis. J Natl Cancer Inst 2005;97:188—94.
13. Семиглазов В.Ф., Семиглазов В.В., Клецель А.Е. Неинвазивные и инвазивные опухоли молочной железы. С.-Пб.; 2006.
14. Forguet A., Campana F., Scholl S. et al. Primary Chemotherapy of primary radiotherapy: a possibility to preserve the breast in large tumors. International Congress of Radiation Oncology 1993. June 21-25 Kyoto; 1993. p. 112.
15. Colleoni M., Litman H.J., Castiglione-Gertsch M. et al. International Breast Cancer Study Group; German Breast Cancer Study Group. Duration of adjuvant chemother- apy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer 2002;86(11):1705—14.
16. Fisher E.R., Wang J., Bryant J. et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002;95(4):681—95.
17. Taghian A.G., Jeong J.H., Mamounas E.P. et al. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol 2006;24(24):3927—32.
Review
For citations:
Maximov K.V., Visotzkaya I.V., Yermilova V.D., Letyagin V.P., Pogodina Ye.M., Chemeris G.Yu., Zikiryakhodzhayev A.D., Kim Ye.A., Martinova G.V. TREATMENT OF THE T3—4N0M0 BREAST CANCER. Tumors of female reproductive system. 2008;(1):20-24. (In Russ.) https://doi.org/10.17650/1994-4098-2008-0-1-20-24
Views:
533
Email this article 